Pharmaceutical company Almirall, a CataloniaBio & HealthTech member, and biotechnology firm Tyris Therapeutics have announced a new alliance to develop non-viral gene therapies to treat minority dermatology diseases.
Tyris has cutting-edge proprietary technology and will be in charge of generating the drugs through to clinical trials. The Spanish biotech company is funded by Columbus Venture Partners.
The deal is part of Almirall’s strategy to offer innovative medical solutions for skin health.
AtCDF3 gene induced greater production of sugars a...
Un estudio con datos de los últimos 35 años, ind...
Un equipo de investigadores de la Universidad Juli...
En nuestro post hablamos sobre este interesante tipo de célula del...
Theriva™ Biologics has announced the presentation of preclinical da...
Biotechnology portal in Spain
Subscribe to our newsletter and stay up to date with the latest news and deals!
2013 © Biotech-Spain.com - Site Developments SL. All Rights Reserved. Terms of Service | Privacy Policy
Articles
Directory